Charcot-Marie-Tooth disease and vincristine
- PMID: 12756314
- DOI: 10.7547/87507315-93-3-229
Charcot-Marie-Tooth disease and vincristine
Abstract
This article reports on a case of sensorimotor neuropathy in a 55-year-old man that developed after vincristine therapy. Subsequent biopsy of the sural nerve and electromyographic studies revealed the presence of Charcot-Marie-Tooth disease. Only 17 patients who developed severe neuropathy with very low accumulated doses of vincristine have been described in the literature. Pain and lateral ankle instability were treated with a functional orthosis. Orthopedic treatment and the biomechanical basis of foot and ankle problems in patients with vincristine therapy-induced Charcot-Marie-Tooth disease are discussed.
Similar articles
-
Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease.Med Pediatr Oncol. 1996 Apr;26(4):280-3. doi: 10.1002/(SICI)1096-911X(199604)26:4<280::AID-MPO12>3.0.CO;2-J. Med Pediatr Oncol. 1996. PMID: 8600343
-
Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A.Arch Dis Child. 1999 Nov;81(5):442-3. doi: 10.1136/adc.81.5.442. Arch Dis Child. 1999. PMID: 10519723 Free PMC article.
-
Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease.BMJ Case Rep. 2017 Apr 24;2017:bcr2016218981. doi: 10.1136/bcr-2016-218981. BMJ Case Rep. 2017. PMID: 28438772 Free PMC article.
-
Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.J Pediatr Hematol Oncol. 2003 Apr;25(4):316-20. doi: 10.1097/00043426-200304000-00010. J Pediatr Hematol Oncol. 2003. PMID: 12679647 Review.
-
Vincristine neurotoxicity in the presence of hereditary neuropathy.Med Pediatr Oncol. 2003 Jan;40(1):39-43. doi: 10.1002/mpo.10105. Med Pediatr Oncol. 2003. PMID: 12426685 Review. No abstract available.
Cited by
-
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.Cancer. 2018 Jul 15;124(14):3052-3065. doi: 10.1002/cncr.31382. Epub 2018 May 9. Cancer. 2018. PMID: 29742281 Free PMC article.
-
Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.Contemp Oncol (Pozn). 2012;16(1):72-8. doi: 10.5114/wo.2012.27341. Epub 2012 Feb 29. Contemp Oncol (Pozn). 2012. PMID: 23788859 Free PMC article.
-
Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).Clin Case Rep. 2022 May 5;10(5):e05766. doi: 10.1002/ccr3.5766. eCollection 2022 May. Clin Case Rep. 2022. PMID: 35540715 Free PMC article.
-
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Front Pharmacol. 2017 Feb 24;8:86. doi: 10.3389/fphar.2017.00086. eCollection 2017. Front Pharmacol. 2017. PMID: 28286483 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical